CASIA OpenIR  > 中国科学院分子影像重点实验室
Upfront dose-reduced chemotherapy synergizes with immunotherapy to optimize chemoimmunotherapy in squamous cell lung carcinoma
He, Xiran1,2; Du, Yang2,3; Wang, Zhijie1; Wang, Xin1; Duan, Jianchun1; Wan, Rui1; Xu, Jiachen1; Zhang, Pei1,2; Wang, Di1,2; Tian, Yanhua4; Han, Jiefei1; Fei, Kailun1; Bai, Hua1; Tian, Jie2,5; Wang, Jie1
Source PublicationJOURNAL FOR IMMUNOTHERAPY OF CANCER
2020
Volume8Issue:2Pages:15
Corresponding AuthorBai, Hua(baihuahb@sina.com) ; Tian, Jie(jie.tian@ia.ac.cn) ; Wang, Jie(zlhuxi@163.com)
AbstractBackground The survival benefits of combining chemotherapy (at the maximum tolerated dose, MTD) with concurrent immunotherapy, collectively referred to as chemoimmunotherapy, for the treatment of squamous cell lung carcinoma (SQCLC) have been confirmed in recent clinical trials. Nevertheless, optimization of chemoimmunotherapy in order to enhance the efficacy of immune checkpoint inhibitors (ICIs) in SQCLC remains to be explored. Methods Cell lines, syngeneic immunocompetent mouse models, and patients' peripheral blood mononuclear cells were used in order to comprehensively explore how to enhance ectopic lymphoid-like structures (ELSs) and upregulate the therapeutic targets of anti-programmed death 1 (PD-1)/anti-PD-1 ligand (PD-L1) monoclonal antibodies (mAbs), thus rendering SQCLC more sensitive to ICIs. In addition, molecular mechanisms underlying optimization were characterized. Results Low-dose chemotherapy contributed to an enhanced antigen exposure via the phosphatidylinositol 3-kinase/Akt/transcription factor nuclear factor kappa B signaling pathway. Improved antigen uptake and presentation by activated dendritic cells (DCs) was observed, thus invoking specific T cell responses leading to systemic immune responses and immunological memory. In turn, enhanced antitumor ELSs and PD-1/PD-L1 expression was observed in vivo. Moreover, upfront metronomic (low-dose and frequent administration) chemotherapy extended the time window of the immunostimulatory effect and effectively synergized with anti-PD-1/PD-L1 mAbs. A possible mechanism underlying this synergy is the increase of activated type I macrophages, DCs, and cytotoxic CD8(+) T cells, as well as the maintenance of intestinal gut microbiota diversity and composition. In contrast, when combining routine MTD chemotherapy with ICIs, the effects appeared to be additive rather than synergistic. Conclusions We first attempted to optimize chemoimmunotherapy for SQCLC by investigating different combinatorial modes. Compared with the MTD chemotherapy used in current clinical practice, upfront metronomic chemotherapy performed better with subsequent anti-PD-1/PD-L1 mAb treatment. This combination approach is worth investigating in other types of tumors, followed by translation into the clinic in the future.
Keyworddrug therapy combination immunotherapy lung neoplasms lymphocytes tumor-infiltrating translational medical research
DOI10.1136/jitc-2020-000807
WOS KeywordIMMUNE CHECKPOINT INHIBITORS ; 2ND-LINE TREATMENT ; CANCER ; THERAPY ; IMMUNOMODULATION ; INFLAMMATION ; COMBINATION ; MICROBIOTA ; CISPLATIN ; REGIMENS
Indexed BySCI
Language英语
Funding ProjectMinistry of Science and Technology of China[2017YFA0205] ; Ministry of Education Innovation Team Development Project[IRT-17R10] ; National Natural Science Foundation of China[81871514] ; National Natural Science Foundation of China[81227901] ; National Natural Science Foundation of China[81470083] ; National Natural Science Foundation of China[91859119] ; National Natural Sciences Foundation Key Program[81630071] ; National Key Research and Development Project[2019YFC1315700] ; CAMS Innovation Fund for Medical Sciences[CIFMS 2016-I2M-3-008] ; CAMS Key Lab of Translational Research on Lung Cancer[2018PT31035] ; Aiyou Foundation[KY201701]
Funding OrganizationMinistry of Science and Technology of China ; Ministry of Education Innovation Team Development Project ; National Natural Science Foundation of China ; National Natural Sciences Foundation Key Program ; National Key Research and Development Project ; CAMS Innovation Fund for Medical Sciences ; CAMS Key Lab of Translational Research on Lung Cancer ; Aiyou Foundation
WOS Research AreaOncology ; Immunology
WOS SubjectOncology ; Immunology
WOS IDWOS:000587927100006
PublisherBMJ PUBLISHING GROUP
Sub direction classification其他
Citation statistics
Cited Times:31[WOS]   [WOS Record]     [Related Records in WOS]
Document Type期刊论文
Identifierhttp://ir.ia.ac.cn/handle/173211/41735
Collection中国科学院分子影像重点实验室
Corresponding AuthorBai, Hua; Tian, Jie; Wang, Jie
Affiliation1.Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Canc Hosp, Dept Med Oncol,Natl Canc Ctr, Beijing, Peoples R China
2.Univ Chinese Acad Sci, Inst Automat, State Key Lab Management & Control Complex Syst, CAS Key Lab Mol Imaging, Beijing, Peoples R China
3.Univ Chinese Acad Sci, Beijing, Peoples R China
4.UT MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX USA
5.Beihang Univ, Beijing Adv Innovat Ctr Big Data Based Precis Med, Sch Med, Beijing, Peoples R China
First Author AffilicationInstitute of Automation, Chinese Academy of Sciences
Corresponding Author AffilicationInstitute of Automation, Chinese Academy of Sciences
Recommended Citation
GB/T 7714
He, Xiran,Du, Yang,Wang, Zhijie,et al. Upfront dose-reduced chemotherapy synergizes with immunotherapy to optimize chemoimmunotherapy in squamous cell lung carcinoma[J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER,2020,8(2):15.
APA He, Xiran.,Du, Yang.,Wang, Zhijie.,Wang, Xin.,Duan, Jianchun.,...&Wang, Jie.(2020).Upfront dose-reduced chemotherapy synergizes with immunotherapy to optimize chemoimmunotherapy in squamous cell lung carcinoma.JOURNAL FOR IMMUNOTHERAPY OF CANCER,8(2),15.
MLA He, Xiran,et al."Upfront dose-reduced chemotherapy synergizes with immunotherapy to optimize chemoimmunotherapy in squamous cell lung carcinoma".JOURNAL FOR IMMUNOTHERAPY OF CANCER 8.2(2020):15.
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
Google Scholar
Similar articles in Google Scholar
[He, Xiran]'s Articles
[Du, Yang]'s Articles
[Wang, Zhijie]'s Articles
Baidu academic
Similar articles in Baidu academic
[He, Xiran]'s Articles
[Du, Yang]'s Articles
[Wang, Zhijie]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[He, Xiran]'s Articles
[Du, Yang]'s Articles
[Wang, Zhijie]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.